Breast Cancer Advice. Keep up to date with the latest information and treatment of breast cancer.
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Device Tracks Progress of Lung Cancer

Ivanhoe Newswire

By Kirsten Houmann, Ivanhoe Health Correspondent

ORLANDO, Fla. (Ivanhoe Newswire) -- Better treatment may be on the horizon for lung cancer patients, thanks to a new device.

Advertisement
Related Stories
 border=
New Screening Catches More Breast Cancers
Breast Cancer Drug Not Tied to Cognitive Decline: Study
Normal Cells May Predict Cancer Virulence
Related Videos
 border=
A Welcome Message from Survivor PJ Hamel
Smother Says "Cut!"
Maryann and Paula
Related Slides
 border=
Breast Cancer
Breast Self-Exam

A microchip-based device previously used to detect circulating tumor cells (CTCs), or tumor cells in the bloodstream, can now be used to analyze genetic changes in those cells. This means the device can help determine how sensitive the cancerous tumors are to drugs called TKIs (Iressa and Tarceva). The devices newfound ability may help doctors form better courses of treatment for lung cancer patients.

Now we have a way to, in a non-invasive manner, tell what the genetic signature of the cancer is and how it changes over time, and that might help us pick better treatments for our patients, Lecia Sequist, M.D., M.P.H., an instructor of medicine at Harvard Medical School and co-author of the study, told Ivanhoe.

The CTC-chip can do more than simply detect CTCs because it doesnt kill the cells like similar devices already on the market, Dr. Sequist explained.

Researchers used the device, called the CTC-chip, to analyze blood samples from 27 non-small-cell lung cancer (NSCLC) patients. Genetic analysis of CTCs from mutation-positive tumors detected mutations 92 percent of the time. NSCLC is the leading cause of cancer death in the United States.

In a previous study, researchers found the device could also capture CTCs from other types of cancer like breast, prostate and colon cancer.

Our next step is to try and see if some of these molecular changes that are pertinent to other tumors can be demonstrated in the captured circulating tumor cells from those kinds of patients as well, Dr. Sequist said.

SOURCE: Ivanhoe interview with Lecia Sequist, M.D., M.P.H.; New England Journal of Medicine, published online July 2, 2008

If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Lindsay Braun at lbraun@ivanhoe.com.


 

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.


Last updated 7/8/2008



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Sep 5, 2008
Home
Search
Powered By HealthLine
New! For timely and trustworth health information, expert advice and much more, visit Breast Cancer Connection
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: